metabolic engineering 9 2007 142 151150 l phenylalanine over producing atcc 31884 strain  (ATCC)

Journal: OncoTargets and therapy

Article Title: RAP80 expression in breast cancer and its relationship with apoptosis in breast cancer cells

doi: 10.2147/OTT.S186981

Figure Lengend Snippet: Representative immunohistochemical staining of RAP80 positive expression in breast cancer tissue and paired normal breast tissue. Note: Positive nucleus staining of RAP80 in the paired normal breast mammary epithelium ( A , B ), RAP80 expression in ductal carcinoma in situ ( C ), and invasive ductal cancer ( D ); original magnification, all ×200.

Article Snippet: Control RAP80 siRNA (sc-92007, 1:500, Santa Cruz Biotechnology Inc., Dallas, TX, USA) and negative control siRNA (sc-36869, 1:500, Santa Cruz Biotechnology Inc.) were used in Western blot analysis to verify the downregulation of RAP80.

Techniques: Immunohistochemical staining, Staining, Expressing, In Situ

Journal: OncoTargets and therapy

Article Title: RAP80 expression in breast cancer and its relationship with apoptosis in breast cancer cells

doi: 10.2147/OTT.S186981

Figure Lengend Snippet: Expression of RAP80 in 162 patients with breast cancer by immunohistochemistry

Article Snippet: Control RAP80 siRNA (sc-92007, 1:500, Santa Cruz Biotechnology Inc., Dallas, TX, USA) and negative control siRNA (sc-36869, 1:500, Santa Cruz Biotechnology Inc.) were used in Western blot analysis to verify the downregulation of RAP80.

Techniques: Expressing, Amplification

Journal: OncoTargets and therapy

Article Title: RAP80 expression in breast cancer and its relationship with apoptosis in breast cancer cells

doi: 10.2147/OTT.S186981

Figure Lengend Snippet: Expression of RAP80 in 67 patients with breast cancer by qRT-PCR

Article Snippet: Control RAP80 siRNA (sc-92007, 1:500, Santa Cruz Biotechnology Inc., Dallas, TX, USA) and negative control siRNA (sc-36869, 1:500, Santa Cruz Biotechnology Inc.) were used in Western blot analysis to verify the downregulation of RAP80.

Techniques: Expressing, Amplification, Fluorescence In Situ Hybridization

Journal: OncoTargets and therapy

Article Title: RAP80 expression in breast cancer and its relationship with apoptosis in breast cancer cells

doi: 10.2147/OTT.S186981

Figure Lengend Snippet: Expression patterns of RAP80 in breast cancer cell lines. Notes: Total RNA and proteins were extracted from wild-type MCF-7, ZR-75, and MDA-MB-231, then subjected to qRT-PCR and Western blotting for RAP80. Both protein ( A – D ) and mRNA ( C , E ) expression of RAP80 were observed consistently in MCF-7, but ZR-75 and MDA-MB-231 had very weak RAP80 mRNA and protein expression. Therefore, we picked MCF-7 for transfection with RAP80 siRNA. Data are presented as mean ± SD of three independent experiments, * P <0.05 vs MCF-7 group. Abbreviations: NC, normal control; qRT-PCR, quantitative real-time polymerase chain reaction.

Article Snippet: Control RAP80 siRNA (sc-92007, 1:500, Santa Cruz Biotechnology Inc., Dallas, TX, USA) and negative control siRNA (sc-36869, 1:500, Santa Cruz Biotechnology Inc.) were used in Western blot analysis to verify the downregulation of RAP80.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Transfection, Real-time Polymerase Chain Reaction

Journal: OncoTargets and therapy

Article Title: RAP80 expression in breast cancer and its relationship with apoptosis in breast cancer cells

doi: 10.2147/OTT.S186981

Figure Lengend Snippet: The Effect of RAP80 siRNA transfection on cell proliferation by MTT in wild-type MCF-7 or MCF-7 RAP80 siRNA. Notes: The survival rate of both cells decreased in a dose-dependent manner and the IC50 value for cisplatin in MCF-7 RAP80 siRNA cells was 0.83 µg/mL, and 1.69 µg/mL in wild-type MCF-7. Cell viability was measured by MTT; n=3 for each data point.

Article Snippet: Control RAP80 siRNA (sc-92007, 1:500, Santa Cruz Biotechnology Inc., Dallas, TX, USA) and negative control siRNA (sc-36869, 1:500, Santa Cruz Biotechnology Inc.) were used in Western blot analysis to verify the downregulation of RAP80.

Techniques: Transfection

Journal: OncoTargets and therapy

Article Title: RAP80 expression in breast cancer and its relationship with apoptosis in breast cancer cells

doi: 10.2147/OTT.S186981

Figure Lengend Snippet: RAP80 siRNA transfection decreased the invasive or migrating ability of MCF-7 breast cancer cells. Notes: Transwell migration assay shows the migrating ability of wild-type MCF-7 ( A ), MCF-7-siNC ( B ), and MCF-7 siRAP80 ( C ) at 72 hours after transfection. ( G ) Number of cells migrating onto the lower surfaces of the filter was counted. The transwell migration assay shows the invasive ability of wild-type MCF-7 ( D ), MCF-7-siNC ( E ), and MCF-7 siRAP80 ( F ) at 72 hours after transfection ( H ). Number of cells invading onto the lower surfaces of the filter was counted. Data are presented as mean ± SD of three independent experiments, * P <0.05 vs MCF-7 siRAP80 group. Abbreviation: NC, normal control.

Article Snippet: Control RAP80 siRNA (sc-92007, 1:500, Santa Cruz Biotechnology Inc., Dallas, TX, USA) and negative control siRNA (sc-36869, 1:500, Santa Cruz Biotechnology Inc.) were used in Western blot analysis to verify the downregulation of RAP80.

Techniques: Transfection, Transwell Migration Assay

Journal: OncoTargets and therapy

Article Title: RAP80 expression in breast cancer and its relationship with apoptosis in breast cancer cells

doi: 10.2147/OTT.S186981

Figure Lengend Snippet: RAP80 siRNA transfection upregulated the expression of apoptotic proteins in MCF-7 cells. Notes: Western blot results showed that the siRNA transfection upregulated the protein expression of Caspase-3, cleaved Caspase-3, Apaf-1, Cytochrome C, Bax, and Fas, and it downregulated the mRNA and protein expression of Bcl-2. Protein levels analyzed by Western blot also confirmed this result ( A – G ). Data are presented as mean ± SD of three independent experiments, * P <0.05 vs MCF-7 siRAP80 group.

Article Snippet: Control RAP80 siRNA (sc-92007, 1:500, Santa Cruz Biotechnology Inc., Dallas, TX, USA) and negative control siRNA (sc-36869, 1:500, Santa Cruz Biotechnology Inc.) were used in Western blot analysis to verify the downregulation of RAP80.

Techniques: Transfection, Expressing, Western Blot